FY2026 EPS Estimates for Bio-Techne Co. (NASDAQ:TECH) Lowered by Analyst

Bio-Techne Co. (NASDAQ:TECH) – Equities research analysts at Leerink Partnrs decreased their FY2026 EPS estimates for Bio-Techne in a research note issued on Wednesday, September 18th. Leerink Partnrs analyst P. Souda now anticipates that the biotechnology company will post earnings of $2.11 per share for the year, down from their previous forecast of $2.16. The consensus estimate for Bio-Techne’s current full-year earnings is $1.71 per share.

Other equities analysts also recently issued research reports about the company. Royal Bank of Canada cut their target price on Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 8th. Benchmark reaffirmed a “buy” rating and set a $95.00 price objective on shares of Bio-Techne in a research note on Tuesday, August 13th. Finally, Robert W. Baird increased their target price on shares of Bio-Techne from $81.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.60.

Bio-Techne Price Performance

TECH stock opened at $80.36 on Friday. Bio-Techne has a 52 week low of $51.79 and a 52 week high of $85.57. The firm has a market capitalization of $12.75 billion, a P/E ratio of 63.78, a price-to-earnings-growth ratio of 5.06 and a beta of 1.27. The company has a fifty day simple moving average of $75.23 and a two-hundred day simple moving average of $73.96. The company has a quick ratio of 2.75, a current ratio of 3.87 and a debt-to-equity ratio of 0.15.

Bio-Techne (NASDAQ:TECH) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported $0.49 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.49. The firm had revenue of $306.10 million during the quarter, compared to analyst estimates of $306.49 million. Bio-Techne had a net margin of 14.50% and a return on equity of 12.88%. Bio-Techne’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD boosted its holdings in Bio-Techne by 92.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,746,119 shares of the biotechnology company’s stock valued at $404,470,000 after acquiring an additional 2,755,065 shares during the period. Brown Capital Management LLC grew its holdings in shares of Bio-Techne by 12.4% in the fourth quarter. Brown Capital Management LLC now owns 3,550,990 shares of the biotechnology company’s stock valued at $273,994,000 after purchasing an additional 392,986 shares in the last quarter. Mairs & Power Inc. increased its stake in Bio-Techne by 0.8% during the 4th quarter. Mairs & Power Inc. now owns 3,079,483 shares of the biotechnology company’s stock worth $237,613,000 after buying an additional 25,903 shares during the period. Bank of New York Mellon Corp lifted its holdings in Bio-Techne by 14.0% during the 1st quarter. Bank of New York Mellon Corp now owns 2,862,526 shares of the biotechnology company’s stock worth $201,493,000 after buying an additional 351,645 shares in the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in Bio-Techne by 8.2% during the 2nd quarter. Mackenzie Financial Corp now owns 2,862,260 shares of the biotechnology company’s stock worth $205,081,000 after buying an additional 216,044 shares in the last quarter. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Techne Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 30th. Shareholders of record on Monday, August 19th were paid a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend was Monday, August 19th. Bio-Techne’s dividend payout ratio (DPR) is presently 25.40%.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.